MarginsXMarginsX
Home › Markets › Health Care › COAG

Hemab Therapeutics Holdings Inc. (COAG)

COAG trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$39.05
-4.42% on the day
Market cap
$1.8B
Small cap
Revenue
New registrant: no annual report filed under this company yet
Net income
New registrant: no annual report filed under this company yet

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerCOAG on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2026
SEC CIK0002114044
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials

New registrant: no annual report filed under this company yet.

Warning signs

Cash runway
32.3 months
$239.1M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
$55.5M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-10
Cash and burn$239.1M cash; operating cash flow -$22.2M a quarter.Report 2026-09-30
Shares outstanding46,730,608 (2026-10-30).Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorEY Godkendt Revisionspartnerselskab, Copenhagen, DenmarkPCAOB Form AP 2026-05-05
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $55.5M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$27.3M-$28.3M$239.1MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q3 2026
2026-06-30
Not filed-$24.1M-$22.6M$237.4MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q3 2026
2026-03-31
Not filed-$22.7M-$21.6M$49.9MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q3 2026
2025-09-30
Not filed-$17.1M-$16.4MNot filedNo debt tagsNeeds four quarters10-Q 2026-11-10
Q3 2026
2025-06-30
Not filed-$12.2M-$15.3MNot filedNo debt tagsNeeds four quarters10-Q 2026-11-10
Q3 2026
2025-03-31
Not filed-$15.3M-$13.0MNot filedNo debt tagsNeeds four quarters10-Q 2026-11-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42026-05-01
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10

Source: SEC EDGAR submissions feed, 53 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-16.6%
1 month+37.1%
3 months-24.3%
Year to dateNot enough price history
1 yearNot enough price history
From 52-week high-25.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
RXRXRecursion Pharmaceuticals Inc.$2.90-8.79%$1.8B
MAZEMaze Therapeutics Inc.$33.90-1.25%$1.9B
WWBWindward Bio Group AG Common Shares$30.04+5.40%$1.7B
BCRXBioCryst Pharmaceuticals Inc.$7.45-2.10%$1.9B
ALVOAlvotech$4.41+5.13%$1.7B
REPLReplimune Group Inc.$21.41-2.19%$2.0B
VIRVir Biotechnology Inc.$9.58-3.82%$1.6B
MESOMesoblast Limited$12.45-6.18%$1.6B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier